Serum galectin-3, but not galectin-1, levels are elevated in schizophrenia

implications for the role of inflammation

Kosuke Kajitani, Kazuyuki Yanagimoto, Yusaku Nakabeppu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Previous studies have reported that galectin-3 is involved in inflammatory processes in the central nervous system and that neuroinflammation may play a role in the pathogenesis of schizophrenia. However, the link between schizophrenia and various galectins is unclear. Objective: The objective of the present study is to determine whether galectin, a well-known lectin protein that binds to μ-galactoside, is associated with chronic schizophrenia. Methods: Thirty-six patients with schizophrenia and 36 healthy controls participated in this study. Schizophrenia symptoms were assessed using the Brief Psychiatry Rating Scale (BPRS). Serum galectin-1 and galectin-3 levels were evaluated using ELISA and compared between the participant groups. Correlation analyses were also performed to examine the relationship between BPRS scores and each galectin level. Results: Serum galectin-3 levels were significantly higher in patients with schizophrenia than they were in controls (p = 0.009, d = 0.640); however, serum galectin-1 levels were not significantly different between the groups (p = 0.513). No significant correlation was identified between serum galectin-3 level and the total BPRS score; however, a significant positive correlation was found between the serum galectin-3 level and the positive symptom score of the BPRS (ρ = 0.355; p = 0.033). Additionally, a significant negative correlation was identified between serum galectin-3 levels and the negative symptom score of the BPRS (ρ = −0.387; p = 0.020). Conclusions: Given the high serum levels of galectin-3 found in patients with schizophrenia compared with that in controls, these findings may support the inflammation hypothesis of schizophrenia.

Original languageEnglish
Pages (from-to)2919-2927
Number of pages9
JournalPsychopharmacology
Volume234
Issue number19
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Galectin 1
Galectin 3
Schizophrenia
Inflammation
Psychiatry
Galectins
Serum
Galactosides
Lectins
Central Nervous System
Enzyme-Linked Immunosorbent Assay

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Serum galectin-3, but not galectin-1, levels are elevated in schizophrenia : implications for the role of inflammation. / Kajitani, Kosuke; Yanagimoto, Kazuyuki; Nakabeppu, Yusaku.

In: Psychopharmacology, Vol. 234, No. 19, 01.10.2017, p. 2919-2927.

Research output: Contribution to journalArticle

@article{baec8ffd3b1a4462a689df5101ed561c,
title = "Serum galectin-3, but not galectin-1, levels are elevated in schizophrenia: implications for the role of inflammation",
abstract = "Background: Previous studies have reported that galectin-3 is involved in inflammatory processes in the central nervous system and that neuroinflammation may play a role in the pathogenesis of schizophrenia. However, the link between schizophrenia and various galectins is unclear. Objective: The objective of the present study is to determine whether galectin, a well-known lectin protein that binds to μ-galactoside, is associated with chronic schizophrenia. Methods: Thirty-six patients with schizophrenia and 36 healthy controls participated in this study. Schizophrenia symptoms were assessed using the Brief Psychiatry Rating Scale (BPRS). Serum galectin-1 and galectin-3 levels were evaluated using ELISA and compared between the participant groups. Correlation analyses were also performed to examine the relationship between BPRS scores and each galectin level. Results: Serum galectin-3 levels were significantly higher in patients with schizophrenia than they were in controls (p = 0.009, d = 0.640); however, serum galectin-1 levels were not significantly different between the groups (p = 0.513). No significant correlation was identified between serum galectin-3 level and the total BPRS score; however, a significant positive correlation was found between the serum galectin-3 level and the positive symptom score of the BPRS (ρ = 0.355; p = 0.033). Additionally, a significant negative correlation was identified between serum galectin-3 levels and the negative symptom score of the BPRS (ρ = −0.387; p = 0.020). Conclusions: Given the high serum levels of galectin-3 found in patients with schizophrenia compared with that in controls, these findings may support the inflammation hypothesis of schizophrenia.",
author = "Kosuke Kajitani and Kazuyuki Yanagimoto and Yusaku Nakabeppu",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s00213-017-4683-9",
language = "English",
volume = "234",
pages = "2919--2927",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "19",

}

TY - JOUR

T1 - Serum galectin-3, but not galectin-1, levels are elevated in schizophrenia

T2 - implications for the role of inflammation

AU - Kajitani, Kosuke

AU - Yanagimoto, Kazuyuki

AU - Nakabeppu, Yusaku

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: Previous studies have reported that galectin-3 is involved in inflammatory processes in the central nervous system and that neuroinflammation may play a role in the pathogenesis of schizophrenia. However, the link between schizophrenia and various galectins is unclear. Objective: The objective of the present study is to determine whether galectin, a well-known lectin protein that binds to μ-galactoside, is associated with chronic schizophrenia. Methods: Thirty-six patients with schizophrenia and 36 healthy controls participated in this study. Schizophrenia symptoms were assessed using the Brief Psychiatry Rating Scale (BPRS). Serum galectin-1 and galectin-3 levels were evaluated using ELISA and compared between the participant groups. Correlation analyses were also performed to examine the relationship between BPRS scores and each galectin level. Results: Serum galectin-3 levels were significantly higher in patients with schizophrenia than they were in controls (p = 0.009, d = 0.640); however, serum galectin-1 levels were not significantly different between the groups (p = 0.513). No significant correlation was identified between serum galectin-3 level and the total BPRS score; however, a significant positive correlation was found between the serum galectin-3 level and the positive symptom score of the BPRS (ρ = 0.355; p = 0.033). Additionally, a significant negative correlation was identified between serum galectin-3 levels and the negative symptom score of the BPRS (ρ = −0.387; p = 0.020). Conclusions: Given the high serum levels of galectin-3 found in patients with schizophrenia compared with that in controls, these findings may support the inflammation hypothesis of schizophrenia.

AB - Background: Previous studies have reported that galectin-3 is involved in inflammatory processes in the central nervous system and that neuroinflammation may play a role in the pathogenesis of schizophrenia. However, the link between schizophrenia and various galectins is unclear. Objective: The objective of the present study is to determine whether galectin, a well-known lectin protein that binds to μ-galactoside, is associated with chronic schizophrenia. Methods: Thirty-six patients with schizophrenia and 36 healthy controls participated in this study. Schizophrenia symptoms were assessed using the Brief Psychiatry Rating Scale (BPRS). Serum galectin-1 and galectin-3 levels were evaluated using ELISA and compared between the participant groups. Correlation analyses were also performed to examine the relationship between BPRS scores and each galectin level. Results: Serum galectin-3 levels were significantly higher in patients with schizophrenia than they were in controls (p = 0.009, d = 0.640); however, serum galectin-1 levels were not significantly different between the groups (p = 0.513). No significant correlation was identified between serum galectin-3 level and the total BPRS score; however, a significant positive correlation was found between the serum galectin-3 level and the positive symptom score of the BPRS (ρ = 0.355; p = 0.033). Additionally, a significant negative correlation was identified between serum galectin-3 levels and the negative symptom score of the BPRS (ρ = −0.387; p = 0.020). Conclusions: Given the high serum levels of galectin-3 found in patients with schizophrenia compared with that in controls, these findings may support the inflammation hypothesis of schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=85023200529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023200529&partnerID=8YFLogxK

U2 - 10.1007/s00213-017-4683-9

DO - 10.1007/s00213-017-4683-9

M3 - Article

VL - 234

SP - 2919

EP - 2927

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 19

ER -